Mitoxantrone, Chlorambucil and Prednisolone in the Treatment of Non-Hodgkin's Lymphoma

References

• Hayhoe F. G. J. Chemotherapy in the management of stage III/IV grade 1 non-Hodgkins lymphomas (report No. 17). Clin. Radiol. 1981; 32: 547–552
   PubMed Web of Science ®Google Scholar
• Horning S. J., Rosenberg S. A. The natural history of initially untreated low grade non-Hodgkins lymphomas. N. Engl. J. Med. 1984; 311: 1471–1475
   PubMed Web of Science ®Google Scholar
• Jones L., Cotter F. E., Lord D., Newland A. C. Phase II study of mitoxantrone in combination with chlorambucil and prednisolone for relapsed and refractory non-Hodgkins lymphoma. Haematologic. Oncol. 1990; 8: 41–45
   PubMed Web of Science ®Google Scholar
• French Cooperative Group on chronic lymphocytic leukaemia. Effectiveness of “CHOP” regimen in advanced untreated chronic lymphocytic leukaemia. Lancet 1986; 1: 1346–1349
   PubMed Web of Science ®Google Scholar
• Lister T. A., Cullen M. H., Beard M. E. J., Brearley R. L., Curtis J. M., Wrigley P. F. M., Stansfield A. G., Sutcliffe S. B. J., Malpas J. S., Crowther D. Comparison of combined and single agent chemotherapy in non-Hodgkins lymphoma of favourable histological type. British Medical Journal 1978; 1: 533–537
   PubMed Web of Science ®Google Scholar
• Smith I. E. Mitoxantrone (Novantrone): A review of experimental and early clinical studies. Cancer Treat. Rev. 1983; 10: 103–115
   PubMed Web of Science ®Google Scholar
• Dukart G., Posner L., Henry D., Weiss A. Comparative cardiotoxicity of mitoxantrone versus daunorubicin. Proc. Am. Sov. Clin. Oncol. 1986; 5: C-48, abstract
   Google Scholar
• Gams R. A., Keller J. W., Golomb H. M., Steinberg J., Dukart G. Mitoxantrone in malignant lymphoma. Cancer Treat. Rev. 1983; 10: 69–72
   PubMed Web of Science ®Google Scholar
• Hansen S. W., Nissen N. I., Hansen M. M., Hou-Jenson K., Pedersen-Bjergaard J. High activity of mitoxantrone in previously untreated low grade lymphomas. Cancer Chemother. Pharmacol. 1988; 22: 77–79
   PubMed Web of Science ®Google Scholar
• Bajetta E., Buzzoni R., Valagussa P., Bonnadonna G. Mitoxantrone: An active agent in refractory Non-Hodgkins lymphomas. Am. J. Clin. Oncol. 1988; 11: 100–103
   PubMed Web of Science ®Google Scholar
• Faulds D., Balfour J. A., Chrisp P., Langtry H. D. Mitoxantrone: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 41: 400–449
   PubMed Web of Science ®Google Scholar
• Silver R. T., Case D. C., Jr., Wheeler R. H., Miller T. P., Stein R. S., Stuart J. J., Peterson B. A., Rivkin S. E., Golomb H. M., et al. Multicentre clinical trial of mitoxantrone in non-Hodgkins lymphoma and Hodgkins disease. J. Clin. Oncol. 1991; 9: 754–761
   PubMed Web of Science ®Google Scholar
• Krikorian J. G., Portlock C. S., Cooney P., Rosenberg S. A. Spontaneous regression of non Hodgkins lymphoma: A report of 9 cases. Cancer 1980; 46: 2093–2099
   PubMed Web of Science ®Google Scholar
• Gall E. A., Mallory T. B. Malignant lymphoma. A clinicopathological survey of 618 cases. Am. J. Pathol. 1942; 18: 281–429
   Google Scholar
• Gallagher C. J., Gregory W. M., Jones A. E., Stansfield A. G., Richards M. A., Dhaliwal H. S., Malpas J. S., Lister T. A. Follicular lymphoma. Prognostic factors for response and survival. J. Clin. Oncol. 1986; 4: 1470–1480
   PubMed Web of Science ®Google Scholar
• Vose J. M., Armitage J. O., Weisenberger D. D., Bier-Man P. J., Sorensen S., Hutchins M., Moravec D. F., Howe D., Dowling M. D., Maillard J., Johnson P. S., Pevnick W., Packard W. M., Ockerbloom J., Thompson R. F., Langdon R. M., Jr., Soori G., Thompson R. F. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkins lymphoma. J. Clin. Oncol. 1988; 6: 1838–1844
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P., Chastang C., Herrera A., Desaint B., Renoux M., Gaulard P., Bernard J. F., Brousse N., Boivin P. Age as the main prognostic factor in adult aggressive non-Hodgkins lymphoma. Am. J. Med. 1987; 83: 1075–1079
   PubMed Web of Science ®Google Scholar
• Merigan T. C., Sikora K., Breedan J. H., Levy R., Rosenberg S. A. Preliminary observations on the effect of human leucocyte interferon in non-Hodgkins lymphoma. N. Engl. J. Med. 1978; 299: 1449–1453
   PubMed Web of Science ®Google Scholar
• Smalley R. V., Anderson J. W., Hawkins M. J. Alpha interferon improves the effectiveness of induction chemotherapy in patients with prognostically unfavourable moderately aggressive non-Hodgkins lymphoma. Proc. Am. Soc. Clin. Oncol. 1991; 10: 272, abstract
   Google Scholar
• McLaughlin P., Cabanillas F., Hagemeister F. B., Swan F., Jr., Romaguera J. E., Taylor S., Rodriguez M. A., Valescquez W. S., Redman J. R., Gutterman J. U. CHOP-Bleo plus interferon for stage IV low grade lymphoma. Ann. Oncol. 1993; 4: 205–211
   PubMed Web of Science ®Google Scholar
• Kay A. C., Carrera C. J., Carson D. A., Beutler E., Piro L. D. Phase II trial of 2 chlorodeoxyadenosine in low grade lymphoma. Blood 1989; 74: 121a, abstract
   Google Scholar
• Hickish T., Scrafinowski P., Cunningham D., Oza A., Dorland E., Judson I., Millar B. C., Lister T. A., Rol-Dan A. 2-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies. Br. J. Cancer 1993; 67: 139–143
   PubMed Web of Science ®Google Scholar
• Whelan J. S., Davis C. L., Rule S., Ranson M., Smith O. P., Mehta A. B., Catovsky D., Rohatiner A. Z. S., Lister T. A. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br. J. Cancer 1991; 64: 120–123
   PubMed Web of Science ®Google Scholar
• Kaminski M. S., Zasadny K. R., Francis I. R., Milik A. W., Ross C. W., Moon S. D., Crawford S. M., Burgess J. M., Petry N. A., Butchco M. G., Glenn S. D., Wahl R. L. Radioimmunotherapy of B-cell lymphoma with I131 anti-B1 (anti CD-20) antibody. N. Engl. J. Med. 1993; 329: 459–465
   PubMed Web of Science ®Google Scholar